Founded in May 2010, Beijing Berry Hekang Biotechnology Co., Ltd. (hereinafter referred to as Berry Gene) is a R&D biotechnology company dedicated to the application of high-throughput gene sequencing technology to provide "non-invasive" overall solutions for clinical medical disease screening and diagnosis. The R&D team of Berry Gene is led by Dr. Gao Yang and Dr. Zhou Daixing, who has participated in the design and development of high-throughput sequencers, and is composed of top experimental, R&D, and bioinformatics experts in the field of high-throughput sequencing and clinical genetic testing, and has established cooperative relations with world-renowned research institutions in the field. Berry Gene has become the world's leading research center for high-throughput sequencing technology and application. The company has successively obtained the Zhongguancun high-tech enterprise certification in September 2011, the national high-tech enterprise certification in December 2012, and the successful listing on the A-share main board in August 2017.

In the context of the promotion of biomedicine to a "national strategic emerging industry", Berry Gene took the lead in practicing human genome sequencing technology in clinical testing with its self-developed core technology. In the field of screening and diagnosis of congenital genetic diseases, Berry Gene has developed a full set of independent intellectual property rights of Bebian's "non-invasive DNA prenatal detection" technology (referred to as Babian), which is the first to realize non-invasive prenatal detection of fetal chromosomal diseases. Subsequently, the detection of chromosomal diseases of KENUOAN (referred to as KENOAN) for pre-marriage, pre-pregnancy, prenatal and probands of genetic diseases, and the preimplantation genetic screening of KEZHENAN for preimplantation chromosome number and structural abnormalities in assisted reproductive technology (hereinafter referred to as KEZHENAN) have been developed, further enriching and improving the detection technology system for genetic disease screening and diagnosis. On this basis, Berry and Kang have successively developed detection technologies for non-invasive fetal chromosomal microdeletions, microduplications and non-invasive fetal monogenic disease genotyping, in order to achieve a safe, accurate, efficient and full-coverage clinical genetic disease screening and diagnosis model.

While deepening into the field of genetic disease screening and diagnosis, Berry Gene has successfully launched the world's leading Onconi tumor molecular diagnostic product based on high-throughput sequencing technology in the field of tumor molecular diagnosis, involving targeted drug detection, efficacy monitoring, medication monitoring, tumor susceptibility detection, and tumor personalized medical all-round testing, so as to achieve the overall coverage of tumor molecular detection. Among them, the non-invasive tumor gene detection with cSMART technology with independent intellectual property rights as the core has opened a new clinical model. In addition, the accumulated data of Berry Gene in the fields of prenatal testing, preconception testing, genetic disease testing and tumor detection has been constructed into a large genome database with Chinese population characteristics. Through cooperation with Baylor College of Medicine, Alibaba Cloud and other leading international institutions, Berry Genomics will use cloud storage and cloud computing platforms to realize the simplified terminal application and real-time sharing of genomic data in the future.

So far, Berry gene has formed a technical dimension from the level of chromosome number and structure, chromosome microdeletion and microduplication, and gene level. From the product dimensions of pre-marriage, pre-pregnancy, pre-natal, neonatal and cancer, it is gradually covered; From the interpretation of individual genome data to the analysis of population genome data, and then to the digital dimension of guiding individual genome data interpretation, the three-dimensional development structure is progressive.